Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Williams-Sonoma, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.71 (market cap $5.07B), while Williams-Sonoma, Inc. trades at $245.26 (market cap $29.51B). The key difference: Williams-Sonoma, Inc. is far larger — about 5.8× ACADIA Pharmaceuticals Inc.'s market cap, and Williams-Sonoma, Inc. pays a 1.21% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | WSM | |
|---|---|---|
Market Cap | $5.07B | $29.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.41 | $251.81 |
52-Week Low | $20.06 | $168.64 |
Enterprise Value | $4.19B | $30.35B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
Williams-Sonoma (WSM) trades at $250.82, down 0.39% on the day, with strong profitability metrics including a 13.81% net income margin and 54.01% ROE. The stock shows a bullish technical trend, supported by moving averages, but RSI levels indicate overbought conditions. Recent earnings beats and a solid dividend history highlight operational strength, though valuation ratios like P/E of 28.09 suggest premium pricing. News coverage remains active, focusing on earnings potential and competitive positioning in the home furnishings sector.
WSM presents a mixed outlook: robust fundamentals and consistent earnings beats support upside, but high valuation and technical overbought signals pose near-term risks. Investor sentiment is cautiously optimistic, with a Moderate Buy analyst consensus and a $231.10 price target slightly below current levels. Key risks include consumer discretionary volatility and competitive pressures, while institutional interest and dividend payments offer stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
